Search

Your search keyword '"Miller, Kurt"' showing total 1,721 results
Start Over Author "Miller, Kurt"
1,721 results on '"Miller, Kurt"'

3. First to fire down under

Author

Miller, Kurt F., Capt

Subjects
ARMY - Australia, ROLES AND MISSIONS - Army - Australia, AIR DEFENSES - Australia, ARMY - Corps, Divisions, etc - Australia
Abstract

illus tab chart

Published
1995

4. Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer

Author

Higano, Celestia S., George, Daniel J., Shore, Neal D., Sartor, Oliver, Miller, Kurt, Conti, Peter S., Sternberg, Cora N., Saad, Fred, Sade, Juan Pablo, Bellmunt, Joaquim, Smith, Matthew R., Chandrawansa, Kumari, Sandström, Per, Verholen, Frank, and Tombal, Bertrand

Published
2023
Full Text
View/download PDF

5. Coccoloba-associated xerocomoid boletes (Boletaceae) from the Caribbean and Mexico: Tropicoboletus ruborculus gen. et comb. nov., revision of Xerocomus coccolobae, phylogenetic assessment of Singerocomus guadelupae comb. nov., and type studies of Xerocomus caeruleonigrescens, X. cuneipes, and X. pseudoboletinus var. pini-caribaeae

Author

Gelardi, Matteo, Angelini, Claudio, Biketova, Alona Yu., Suz, Laura M., Ercole, Enrico, Svetasheva, Tatiana Yu., Miller, Kurt O., de la Fuente, Javier Isaac, Jiménez, Jesús García, and Vizzini, Alfredo

Published
2023
Full Text
View/download PDF

6. App-based Therapy of Erectile Dysfunction Using a Digital Health Application (EDDIG Study): A Randomized, Single-blind, Controlled Trial

Author

Kliesch, Sabine, primary, Cremers, Jann-Frederik, additional, Krallmann, Claudia, additional, Epplen, Robin, additional, Scheffer, Bettina, additional, Schubert, Tim, additional, Schubert, Maria, additional, Dreger, Nici Markus, additional, Raschke, Ralph, additional, Khaljani, Ehsan, additional, Maxeiner, Andreas, additional, Miller, Kurt, additional, Wiemer, Laura, additional, and Zitzmann, Michael, additional

Published
2024
Full Text
View/download PDF

9. Selective Antineoplastic Potential of Fractionated Caribbean Native Ganoderma Species Extracts on Triple-Negative Breast Cancer Cells.

Author

Arroyo-Cruz, Luz V., Sagardía-González, Sebastián, Miller, Kurt, Ling, Taotao, Rivas, Fatima, and Martínez-Montemayor, Michelle M.

Subjects
TRIPLE-negative breast cancer, EPIDERMAL growth factor receptors, GANODERMA lucidum, ESTROGEN receptors, CYTOTOXINS, PROGESTERONE receptors
Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor type 2 expression. It is known for its high malignancy, invasiveness, and propensity for metastasis, resulting in a poor prognosis due to the absence of beneficial therapeutic targets. Natural products derived from mushrooms have gained significant attention in neoplastic therapy due to their potential medicinal properties. The therapeutic potential of Ganoderma lucidum in breast cancer has been highlighted by our group, suggesting its use as an adjuvant treatment. The present study aims to assess the potential antineoplastic capacity of two Caribbean native Ganoderma species found in Puerto Rico, Ganoderma multiplicatum (G. multiplicatum) and Ganoderma martinicense (G. martinicense). Antiproliferative studies were conducted via cell viability assays after cultivation, harvesting, and fractionation of both species. The obtained results indicate that most of the fractions show some cytotoxicity against all cell lines, but 33% of the fractions (F1, F2, F7, F12) display selectivity towards cancer cell models. We demonstrate for the first time that native Ganoderma species can generate metabolites with anti-TNBC properties. Future avenues will focus on structure elucidation of the most active fractions of these Ganoderma extracts. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Adressen

Author

Rausch, Steffen, primary, Stenzl, Arnulf, additional, Altgelt, Thomas, additional, Aufderklamm, Stefan, additional, Batra, Anil, additional, Bedke, Jens, additional, Binder, Gerhard, additional, Dinges, Martin, additional, Eigentler, Thomas, additional, Graf, Johanna, additional, Häntschel, Maik, additional, Haider, Maximilian, additional, Hakenberg, Oliver, additional, Hatzichristodoulou, Georgios, additional, Hetzel, Jürgen, additional, Hofmann, Aybike, additional, Kautzky-Willer, Alexandra, additional, Kendel, Friederike, additional, Kliesch, Sabine, additional, Kraeft, Ann-Lena, additional, Kranz, Jennifer, additional, Lawaczeck, Laura, additional, Leutner, Michael, additional, Lugnier, Céline, additional, Mau, Marcus, additional, Miller, Kurt, additional, Münch, Fabian, additional, Neubauer, Gunter, additional, Nies, Andreas, additional, Ong, Peter, additional, Rausch, Steffen, additional, Reinacher-Schick, Anke, additional, Rösch, Wolfgang, additional, Scheffer, Bettina, additional, Seeland, Ute, additional, Sievert, Karl Dietrich, additional, Sokolakis, Ioannis, additional, Sommer, Frank, additional, Sperling, Herbert, additional, Stirn, Valentina Aglaja, additional, Stubbe, Manuela, additional, Voos, Georg, additional, and Zengerling, Friedemann, additional

Published
2022
Full Text
View/download PDF

14. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

Author

Beer, Tomasz M, Armstrong, Andrew J, Rathkopf, Dana, Loriot, Yohann, Sternberg, Cora N, Higano, Celestia S, Iversen, Peter, Evans, Christopher P, Kim, Choung-Soo, Kimura, Go, Miller, Kurt, Saad, Fred, Bjartell, Anders S, Borre, Michael, Mulders, Peter, Tammela, Teuvo L, Parli, Teresa, Sari, Suha, van Os, Steve, Theeuwes, Ad, and Tombal, Bertrand

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Clinical Trials and Supportive Activities, Cancer, Prostate Cancer, Clinical Research, Urologic Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Antineoplastic Agents, Benzamides, Humans, Male, Nitriles, Phenylthiohydantoin, Prostatic Neoplasms, Castration-Resistant, Survival Analysis, Androgen receptor signaling inhibitor, Enzalutamide, Metastatic castration-resistant prostate cancer, Overall survival, Radiographic progression-free survival, Urology & Nephrology, Clinical sciences
Abstract

Enzalutamide significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) among men with chemotherapy-naïve metastatic castration-resistant prostate cancer at the prespecified interim analysis of PREVAIL, a phase 3, double-blind, randomized study. We evaluated the longer-term efficacy and safety of enzalutamide up to the prespecified number of deaths in the final analysis, which included an additional 20 mo of follow-up for investigator-assessed rPFS, 9 mo of follow-up for OS, and 4 mo of follow-up for safety. Enzalutamide reduced the risk of radiographic progression or death by 68% (hazard ratio [HR] 0.32, 95% confidence interval [CI] 0.28-0.37; p

Published
2017

15. Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE).

Author

Higano, Celestia S., Dizdarevic, Sabina, Logue, John, Richardson, Timothy, George, Saby, de Jong, Igle, Tomaszewski, Jeffrey J., Saad, Fred, Miller, Kurt, Meltzer, Jeffrey, Sandström, Per, Verholen, Frank, Tombal, Bertrand, and Sartor, Oliver

Subjects
CASTRATION-resistant prostate cancer, LEUCOCYTES, SCIENTIFIC observation
Abstract

Background: Radium‐223 and taxane chemotherapy each improve survival of patients with metastatic castration‐resistant prostate cancer (mCRPC). Whether the radium‐223–taxane sequence could extend survival without cumulative toxicity was explored. Methods: The global, prospective, observational REASSURE study (NCT02141438) assessed real‐world safety and effectiveness of radium‐223 in patients with mCRPC. Using data from the prespecified second interim analysis (data cutoff, March 20, 2019), hematologic events and overall survival (OS) were evaluated in patients who were chemotherapy‐naive at radium‐223 initiation and subsequently received taxane chemotherapy starting ≤90 days ("immediate") or >90 days ("delayed") after the last radium‐223 dose. Results: Following radium‐223 therapy, 182 patients received docetaxel (172 [95%]) and/or cabazitaxel (44 [24%]); 34 patients (19%) received both. Seventy‐three patients (40%) received immediate chemotherapy and 109 patients (60%) received delayed chemotherapy. Median time from last radium‐223 dose to first taxane cycle was 3.6 months (range, 0.3–28.4). Median duration of first taxane was 3.7 months (range, 0–22.0). Fourteen patients (10 in the immediate and four in the delayed subgroup) had grade 3/4 hematologic events during taxane chemotherapy, including neutropenia in two patients in the delayed subgroup and thrombocytopenia in one patient in each subgroup. Median OS was 24.3 months from radium‐223 initiation and 11.8 months from start of taxane therapy. Conclusions: In real‐world clinical practice settings, a heterogeneous population of patients who received sequential radium‐223–taxane therapy had a low incidence of hematologic events, with a median survival of 1 year from taxane initiation. Thus, taxane chemotherapy is a feasible option for those who progress after radium‐223. Clinical Trial Registration: ClinicalTrials.gov identifier NCT02141438. Plain Language Summary: Radium‐223 and chemotherapy are treatment options for metastatic prostate cancer, which increase survival but may affect production of blood cells as a side effect.We wanted to know what would happen if patients received chemotherapy after radium‐223.Among the 182 men treated with radium‐223 who went on to receive chemotherapy, only two men had severe side effects affecting white blood cell production (neutropenia) during chemotherapy.On average, the 182 men lived for 2 years after starting radium‐223 and 1 year after starting chemotherapy.In conclusion, patients may benefit from chemotherapy after radium‐223 treatment without increasing the risk of side effects. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Smith, Matthew, Parker, Chris, Saad, Fred, Miller, Kurt, Tombal, Bertrand, Ng, Quan Sing, Boegemann, Martin, Matveev, Vsevolod, Piulats, Josep Maria, Zucca, Luis Eduardo, Karyakin, Oleg, Kimura, Go, Matsubara, Nobuaki, Nahas, William Carlos, Nolè, Franco, Rosenbaum, Eli, Heidenreich, Axel, Kakehi, Yoshiyuki, Zhang, Amily, Krissel, Heiko, Teufel, Michael, Shen, Junwu, Wagner, Volker, and Higano, Celestia

Published
2019
Full Text
View/download PDF

24. The Phylogenetic Indian Buffet Process: A Non-Exchangeable Nonparametric Prior for Latent Features

Author

Miller, Kurt T., Griffiths, Thomas, and Jordan, Michael I.

Subjects
Computer Science - Learning, Statistics - Machine Learning
Abstract

Nonparametric Bayesian models are often based on the assumption that the objects being modeled are exchangeable. While appropriate in some applications (e.g., bag-of-words models for documents), exchangeability is sometimes assumed simply for computational reasons; non-exchangeable models might be a better choice for applications based on subject matter. Drawing on ideas from graphical models and phylogenetics, we describe a non-exchangeable prior for a class of nonparametric latent feature models that is nearly as efficient computationally as its exchangeable counterpart. Our model is applicable to the general setting in which the dependencies between objects can be expressed using a tree, where edge lengths indicate the strength of relationships. We demonstrate an application to modeling probabilistic choice., Comment: Appears in Proceedings of the Twenty-Fourth Conference on Uncertainty in Artificial Intelligence (UAI2008)

Published
2012

25. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Author

Beer, Tomasz M, Armstrong, Andrew J, Rathkopf, Dana E, Loriot, Yohann, Sternberg, Cora N, Higano, Celestia S, Iversen, Peter, Bhattacharya, Suman, Carles, Joan, Chowdhury, Simon, Davis, Ian D, de Bono, Johann S, Evans, Christopher P, Fizazi, Karim, Joshua, Anthony M, Kim, Choung-Soo, Kimura, Go, Mainwaring, Paul, Mansbach, Harry, Miller, Kurt, Noonberg, Sarah B, Perabo, Frank, Phung, De, Saad, Fred, Scher, Howard I, Taplin, Mary-Ellen, Venner, Peter M, and Tombal, Bertrand

Subjects
Urologic Diseases, Clinical Trials and Supportive Activities, Prostate Cancer, Clinical Research, Aging, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adenocarcinoma, Administration, Oral, Androgen Receptor Antagonists, Antineoplastic Agents, Hormonal, Benzamides, Disease Progression, Double-Blind Method, Humans, Male, Neoplasm Metastasis, Nitriles, Phenylthiohydantoin, Prostatic Neoplasms, Radiography, Receptors, Androgen, Survival Analysis, PREVAIL Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundEnzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.MethodsIn this double-blind, phase 3 study, we randomly assigned 1717 patients to receive either enzalutamide (at a dose of 160 mg) or placebo once daily. The coprimary end points were radiographic progression-free survival and overall survival.ResultsThe study was stopped after a planned interim analysis, conducted when 540 deaths had been reported, showed a benefit of the active treatment. The rate of radiographic progression-free survival at 12 months was 65% among patients treated with enzalutamide, as compared with 14% among patients receiving placebo (81% risk reduction; hazard ratio in the enzalutamide group, 0.19; 95% confidence interval [CI], 0.15 to 0.23; P

Published
2014

36. Towards User-centered Corpus Development: Lessons Learnt from Designing and Developing MedTator

Author

He, Huan, Fu, Sunyang, Wang, Liwei, Wen, Andrew, Liu, Sijia, Moon, Sungrim, Miller, Kurt, and Liu, Hongfang

Subjects
Articles
Abstract

A gold standard annotated corpus is usually indispensable when developing natural language processing (NLP) systems. Building a high-quality annotated corpus for clinical NLP requires considerable time and domain expertise during the annotation process. Existing annotation tools may provide powerful features to cover various needs of text annotation tasks, but the target end users tend to be trained annotators. It is challenging for clinical research teams to utilize those tools in their projects due to various factors such as the complexity of advanced features and data security concerns. To address those challenges, we developed MedTator, a serverless web-based annotation tool with an intuitive user-centered interface aiming to provide a lightweight solution for the core tasks in corpus development. Moreover, we present three lessons learned from the designing and developing MedTator, which will contribute to the research community’s knowledge for future open-source tool development.

Published
2023

38. Comorbidity and healthcare utilization in patients with treatment resistant depression: A large-scale retrospective cohort analysis using electronic health records

Author

Adekkanattu, Prakash, primary, Olfson, Mark, additional, Susser, Leah C., additional, Patra, Braja, additional, Vekaria, Veer, additional, Coombes, Brandon J., additional, Lepow, Lauren, additional, Fennessy, Brian, additional, Charney, Alexander, additional, Ryu, Euijung, additional, Miller, Kurt D., additional, Pan, Lifang, additional, Yangchen, Tenzin, additional, Talati, Ardesheer, additional, Wickramaratne, Priya, additional, Weissman, Myrna, additional, Mann, John, additional, Biernacka, Joanna M., additional, and Pathak, Jyotishman, additional

Published
2023
Full Text
View/download PDF

43. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial

Author

Loriot, Yohann, Miller, Kurt, Sternberg, Cora N, Fizazi, Karim, De Bono, Johann S, Chowdhury, Simon, Higano, Celestia S, Noonberg, Sarah, Holmstrom, Stefan, Mansbach, Harry, Perabo, Frank G, Phung, De, Ivanescu, Cristina, Skaltsa, Konstantina, Beer, Tomasz M, and Tombal, Bertrand

Published
2015
Full Text
View/download PDF

44. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Author

Ryan, Charles J, Smith, Matthew R, Fizazi, Karim, Saad, Fred, Mulders, Peter F A, Sternberg, Cora N, Miller, Kurt, Logothetis, Christopher J, Shore, Neal D, Small, Eric J, Carles, Joan, Flaig, Thomas W, Taplin, Mary-Ellen, Higano, Celestia S, de Souza, Paul, de Bono, Johann S, Griffin, Thomas W, De Porre, Peter, Yu, Margaret K, Park, Youn C, Li, Jinhui, Kheoh, Thian, Naini, Vahid, Molina, Arturo, and Rathkopf, Dana E

Published
2015
Full Text
View/download PDF

45. Prostate-Specific Antigen Persistence After Radical Prostatectomy as a Predictive Factor of Clinical Relapse-Free Survival and Overall Survival: 10-Year Data of the ARO 96-02 Trial

Author

Wiegel, Thomas, Bartkowiak, Detlef, Bottke, Dirk, Thamm, Reinhard, Hinke, Axel, Stöckle, Michael, Rübe, Christian, Semjonow, Axel, Wirth, Manfred, Störkel, Stephan, Golz, Reinhard, Engenhart-Cabillic, Rita, Hofmann, Rainer, Feldmann, Horst-Jürgen, Kälble, Tilman, Siegmann, Alessandra, Hinkelbein, Wolfgang, Steiner, Ursula, and Miller, Kurt

Published
2015
Full Text
View/download PDF

46. A European Multicenter Randomized Noninferiority Trial Comparing 180 W GreenLight XPS Laser Vaporization and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 12-Month Results of the GOLIATH Study

Author

Bachmann, Alexander, Tubaro, Andrea, Barber, Neil, d’Ancona, Frank, Muir, Gordon, Witzsch, Ulrich, Grimm, Marc-Oliver, Benejam, Joan, Stolzenburg, Jens-Uwe, Riddick, Antony, Pahernik, Sascha, Roelink, Herman, Ameye, Filip, Saussine, Christian, Bruyère, Franck, Loidl, Wolfgang, Larner, Tim, Gogoi, Nirjan-Kumar, Hindley, Richard, Muschter, Rolf, Thorpe, Andrew, Shrotri, Nitin, Graham, Stuart, Hamann, Moritz, Miller, Kurt, Schostak, Martin, Capitán, Carlos, Knispel, Helmut, and Thomas, J. Andrew

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results